Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2017-07-20
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of pasireotide and to see how
well it works when given together with docetaxel and prednisone in treating patients with
metastatic hormone-resistant prostate cancer. Drugs used in chemotherapy, such as docetaxel
and prednisone, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Pasireotide may inhibit the secretion of
hormones. Giving pasireotide together with docetaxel and prednisone may kill more tumor
cells.